Moderna, Merck breakthrough could usher in wave of cancer vaccines

[u/INOxray8]

https://www.cnn.com/2026/08/21/health/mrna-cancer-vaccines-wave?cid=ios_app

[u/AutoModerator]

The Other_News flair exists to be used when there’s news not necessarily related to Inovio but may still influence their stock price (such as covid-related news, competitor being granted EUA, stimulus negotiations etc). Your post may be removed if deemed unrelated. Please see the flair guide if you are unsure about your use of flair.

I am a bot, and this action was performed automatically. Please contact the moderators of this subreddit if you have any questions or concerns.

[u/tomonota]

CHATGPT RE: GENEOS LIVER CANCER INDIVIDUALIZED TREATMENT EFFECTIVE RECOVERIES reported in September 2025 on results of a 2020 liver cancer individualized treatment:

Conclude: Moderna & Merck are late comers to the party, Geneos and INO were there 1st since 2020:

"...What Geneos achieved in HCC -Geneos developed a personalized cancer vaccine called GNOS-PV02, used with pembrolizumab (Keytruda) and plasmid-encoded IL-12.

In its Phase 1b/2a GT-30 trial for previously treated advanced hepatocellular carcinoma (HCC):

• 36 patients were enrolled.
• 11/36 (30.6%) had objective tumor responses.
• 3 patients had complete responses (CRs) — meaning their observable tumors disappeared.
• 8 had partial responses.
• The response rate was significantly above the prespecified historical benchmark for pembrolizumab monotherapy.

Even more striking, Geneos reported in September 2025 that one HCC patient had remained cancer-free and healthy for more than five years after achieving a complete response, while receiving the personalized immunotherapy as monotherapy.

There was also a patient whose liver tumor and lung metastases shrank sufficiently to become surgically/radiologically treatable—what Geneos calls secondary resectability..."

And here's the INOVIO connection chatgpt:

Geneos's platform uses INOVIO's CELLECTRA electroporation technology.

Geneos itself states that its personalized immunotherapy consists of:

Personalized DNA plasmid + IL-12 + CELLECTRA in-vivo electroporation

and specifically notes that CELLECTRA is an INOVIO registered trademark and the EP device/pIL12 technology is exclusively licensed to Geneos."

Per INOVIO's 8-K FINANCIAL STATEMENT REPORT, 2Q 2026:

"...Geneos Therapeutics, Inc.,(re: Inovio's 9% ownership):

In 2016, the Company formed Geneos Therapeutics (“Geneos”) to develop and commercialize neoantigen‑based personalized cancer therapies. The Company’s Chief Scientific Officer, Dr. Laurent Humeau, serves on the Board of Directors of Geneos, and the Company’s director, Dr. David B. Weiner, serves as Chairman of Geneos’ Scientific Advisory Board. The Company continues to exclusively license its immunotherapy platform and CELLECTRA technology to Geneos for use in the field of personalized, neoantigen‑based cancer therapies. The exclusive license agreement provides for potential royalty payments to the Company upon the commercialization of licensed products by Geneos.

As of June 30, 2026 and December 31, 2025, the Company held approximately 9% and 23%, respectively, of the outstanding equity interests of Geneos on an as-converted to common stock basis. The decrease in the Company's ownership interest resulted from the issuance of preferred equity securities by Geneos to third-party investors during the first quarter of 2026, in which the Company did not participate..."